Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory
Moo Hyun Kim, Young Seok Lee, Michael S. Lee
04 December 2014
April 2014, 22:7
1.Appleton DL, Cooke RH, Rao SV, Jovin IS. Anticoagulation in transradial percutaneous coronary intervention. Catheter Cardiovasc Interv 2014;83(2):237–42.
2.Levine GN, Bate ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124: e574–e651.
3.White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 2006; 152: 1042–50.
4.Fifth Organization to Assess Strategies in Acute Ischemic Syndromes investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464–76.
5.Lincoff AM, Bittl JA, Harrington RA, et al, for the REPLACE-2 investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853–63.
6.Stone GW, Witzenbichler B, Guagliumi G, et al. HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218–30.
7.Kim MH, Yu LH, Tanaka H, Mitsudo K. Experience with a novel retrograde wiring technique for coronary chronic total occlusion. J Interv Cardiol 2013;26(3):254–8.
8.Muramatsu T. Current technical and clinical features of the antegrade and retrograde approaches to percutaneous transluminal coronary intervention for chronic total occlusion-2013 version. Syllabus of TOPIC meeting 2013. p179.
9.Sharman S, Patel S, Behl A, et al. Extensive Fatal Intracoronary Thrombosis During Percutaneous Coronary Intervention With Bivalirudin. Am J Ther 2013 Jul 25 [Epub ahead of print].
10.Stone GW, McLaurin BT, Cox DA, et al, for the ACUITY investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203–16.
11.Dangas GD, Mehran R, Nikolsky E, et al. Effect of switching anti-thrombotic agents for primary angioplasty in acute myocardial infarction. The HORIZONS-SWITCH analysis. J Am Coll Cardiol 2011;57:2309–2316.
12.Koutouzis M, Lagerqvist B, James S, et al. Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Heart 2011;97 (18):1484–8.
13.Langrish JP, Fox KAA. Optimal antithrombotic treatment during primary percutaneous coronary intervention? Heart 2011;97:1459–60.
14.Shahzad A, Cooper RM, Stables RH. Anthithrombotic therapy in PCI: Why not heprin? Eurointervention 2013;22:423–6.